Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Creon

- PMLiVE

Valeant takeover bid for Allergan turns hostile

Canadian firm goes directly to shareholders with offer

- PMLiVE

Allergan rebuffs Valeant once again

Could lead to hostile takeover bid

- PMLiVE

Valeant steps up pressure on Allergan with raised bid

Ups price yet again in attempt to acquire company behind Botox

- PMLiVE

Valeant sweetens Allergan offer with help from Nestle deal

Will divest skincare treatments to sidestep product conflict issues

Roche - Basel

CHMP turns down Avastin for brain cancer

Roche set to be denied expanded use for oncology drug in Europe

- PMLiVE

CHMP backs European approval for six new medicines

Recommends drugs by PTC Therapeutics, Roche, Biogen Idec, Octapharma, Alcon and Veloxis Pharma

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

- PMLiVE

Battle lines drawn as Allergan rejects Valeant offer

Turns down $47bn takeover bid saying it undervalues the company

- PMLiVE

Bayer’s Nexavar recommended for thyroid cancer in EU

CHMP backs extra indication for cancer drug

- PMLiVE

GSK’s Mekinist on course for EU melanoma approval

Only new medicine recommended in latest CHMP opinions

- PMLiVE

Allergan resists Valeant’s advances

Threatens to derail proposed $45bn merger

- PMLiVE

Valeant offers $45.7bn for Botox firm Allergan

Trend for major pharma deals continues

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links